UNITED STATES PATENT AND TRADEMARK
`OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL
`BOARD
`
`APOTEX, INC.,
`Petitioner,
`v.
`CELGENE CORPORATION,
`Patent Owner.
`
`Case IPR2023-00512
`Patent 8,846,628
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION
`PRO HAC VICE OF NORA Q.E. PASSAMANECK
`
`
`OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL
`BOARD
`
`APOTEX, INC.,
`Petitioner,
`v.
`CELGENE CORPORATION,
`Patent Owner.
`
`Case IPR2023-00512
`Patent 8,846,628
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION
`PRO HAC VICE OF NORA Q.E. PASSAMANECK
`
`
`
`IPR2023-00512
`Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`Statement of Precise Relief Requested
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Bristol-Myers Squibb Co.
`
`
`I.
`
`requests that the Patent Trial and Appeal Board (the “Board”) admit Nora Q.E.
`
`Passamaneck pro hac vice in this proceeding, IPR2023-00512. The parties have
`
`conferred, and Petitioner does not oppose this motion.
`
`II.
`
`Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice during a proceeding upon a showing of good cause, subject to the
`
`condition that lead counsel be a registered practitioner and to any other conditions
`
`the Board may impose. Section 42.10(c) indicates that, “where the lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon a showing that counsel is an
`
`experienced litigating attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.” The facts here establish good cause for the
`
`Board to recognize Nora Q.E. Passamaneck pro hac vice in this proceeding.
`
`1.
`
`Lead counsel, Heather M. Petruzzi, is a registered practitioner.
`
`Backup counsel Laura Macro and Gabriel Rosanio are also registered practitioners.
`
`2.
`
`Nora Q.E. Passamaneck is an experienced attorney who has an
`
`established familiarity with the subject matter at issue in the proceeding.
`
`2
`
`
`
`IPR2023-00512
`Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`
`Accompanying this motion as Exhibit 2153 is the Declaration of Nora Q.E.
`
`Passamaneck in Support of this Motion for Admission Pro Hac Vice
`
`(“Passamaneck Decl.”). In her declaration, Ms. Passamaneck asserts:
`
`I am a member in good standing of the Bars of the Commonwealth of
`
`Massachusetts, State of New York, and State of Colorado. I am
`
`admitted to practice before the U.S. District Courts for the District of
`
`Colorado, District Court for the Eastern District of New York, and
`
`District Court for the Southern District of New York. I am also
`
`admitted to practice before the U.S. Court of Appeals for the Federal
`
`Circuit and the Tenth Circuit.
`
`Passamaneck Decl. ¶ 3 (Ex.2153). Ms. Passamaneck also demonstrates that she
`
`has a detailed working knowledge of the relevant subject matter through her
`
`familiarity with pharmaceutical technologies as a result of participation as counsel
`
`in related district court litigations on this patent as well as many prior
`
`pharmaceutical-related intellectual property cases on behalf of BMS/Celgene and
`
`other pharmaceutical companies. Passamaneck Decl. ¶ 5–6 (Ex.2153).
`
`3.
`
`In her declaration, Ms. Passamaneck also attests to each of the listed
`
`items required by the Order – Notice of Filing Date Accorded to Petition And
`
`Time For Filing Patent Owner Preliminary Response – 37 C.F.R. § 42.10(c) in
`
`3
`
`
`
`IPR2023-00512
`Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`
`IPR2023-00512. See Passamaneck Decl. ¶ 10 (Ex.2153). Ms. Passamaneck attests
`
`that she has read and will comply with the Patent Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in 35 C.F.R. § 42. Id.,
`
`¶ 11. Ms. Passamaneck further attests that she agrees to be subject to the United
`
`States Patent and Trademark Office’s Rules of Professional Conduct as set forth in
`
`37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a). Id., ¶ 12.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`IPR2023-00512
`Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`
`III. Conclusion
`For the foregoing reasons, and in view of the Declaration submitted herewith
`
`(Ex.2153), Patent Owner respectfully requests that the Board grant this motion and
`
`admit Ms. Passamaneck pro hac vice in this proceeding. The undersigned
`
`authorizes the Office to charge $250 to Deposit Account No. 08-0219 for the fees
`
`set forth in 37 C.F.R. § 42.15(e) for this pro hac vice motion. Please charge any
`
`shortage of fees or credit any overpayments to the above Deposit Account.
`
`
`Dated: October 25, 2023
`
`
`Respectfully submitted,
`
`
`
`/Heather M. Petruzzi/
`
`Heather M. Petruzzi (Reg. No. 71,270)
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`2100 Pennsylvania Ave NW
`Washington, DC 20037
`(202) 663-6028
`
`
`
`5
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`PATENT OWNER’S EXHIBIT LIST IPR2023-00512
`
`Exhibit No.
`
`Description
`
`2001
`
`Declaration of Dr. Corey Berkland
`
`
`
`
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`U.S. Food and Drug Admin., FDA approves Onureg® (azacitidine
`tablets) for acute myeloid leukemia (2020),
`https://www.fda.gov/drugs/resources-information-approved-
`drugs/fda-approves-onureg-azacitidine-tablets-acute-myeloid-
`leukemia (“FDA Approves Onureg®”)
`
`Aparicio, A. & Weber, J., Review of the clinical experience with 5-
`azacytidine and 5-aza-2’-deoxycytidine in solid tumors, 3 CURRENT
`OPINION IN INVESTIGATIONAL DRUGS 627–633 (2002) (“Aparicio”)
`
`Beisler, J., et al., Chemistry of Antitumor Triazine Nucleosides. An
`Improved Synthesis of Dihydro-5-Azacytidine, 4(5) J.
`CARBOHYDRATES NUCLEOSIDES NUCLEOTIDES 281–99 (1977)
`(“Beisler”)
`
`Reserved
`
`Canadian Product 200mg Onureg® Product Information
`
`Canadian Product 300mg Onureg® Product Information
`
`Canadian Product Monograph Onureg®
`
`Chabner, B., et al., Deamination of 5-azacytidine by a human
`leukemia cell cytidine deaminase, 22 BIOCHEMICAL PHARMACOLOGY
`2763–65 (1973) (“Chabner”)
`
`Chen, X., et al., Highly Efficient Regioselective Synthesis of 5’-O-
`lauroyl-5-azacytidine Catalyzed by Candida antarctica Lipase B, 151
`APPL. BIOCHEM. BIOTECHNOL. 21–28 (2008) (“Chen”)
`
`6
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`Cheung, Y., et al., Stability of azacitidine in infusion fluids, 41 AM.
`J. OF HOSP. PHARMACY 1156–59 (1984) (“Cheung”)
`
`Čihák, A & Šorm, F., Biochemical Effects and Metabolic
`Transformations of 5-Azacytidine in Escherichia coli, 30 COLLECT.
`CZECH. CHEM. COMMUN. 2091–2102 (1965) (“Čihák”)
`
`European Commission Decision 17.6.21
`
`CONNORS, K., ET AL., CHEMICAL STABILITY OF PHARMACEUTICALS: A
`HANDBOOK FOR PHARMACISTS 239 (2nd Ed. 1986) (“Connors”)
`
`Evans, D., et al., Measurement of gastrointestinal pH profiles in
`normal ambulant human subjects, 29 GUT 1035–41 (1988)
`(“Evans”)
`
`Perrie, Y. & Rades, T., PHARMACEUTICAL: DRUG DELIVERY AND
`TARGETING (2010) (“FASTtrack”)
`
`Gaubert, G., et al., Unnatural Enantiomers of 5-azacytidine
`Analogues: Syntheses and Enzymatic Properties, 20(4–7)
`NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS 837–40 (2001)
`(“Gaubert”)
`
`Kaminskas, E., et al., FDA Drug Approval Summary: Azacitidine (5-
`azacytidine, Vidaza™) for Injectable Suspension, 10 THE
`ONCOLOGIST 176–82 (2005) (“Kaminskas”)
`
`Kissinger, L. & Stemm, N., Determination of the Antileukemia
`Agents Cytarabine and Azacitidine and Their Respective
`Degradation Products by High-Performance Liquid
`Chromatography, 353 J. OF CHROMATOGRAPHY 309–18 (1986)
`(“Kissinger”)
`
`LIEBERMAN, H., ET AL., PHARMACEUTICAL DOSAGE FORMS: TABLETS
`3 (2nd Ed. 1990) (“Lieberman”)
`
`7
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`Lin, K., et al., High -Performance Liquid Chromatographic Analysis
`of Chemical Stability of 5-Aza-2’-deoxycytidine, 70 J. OF
`PHARMACEUTICAL SCI. 1228–32 (1981) (“Lin”)
`
`Mund, C., Reactivation of Epigenetically Silenced Genes by DNA
`Methyltransferase Inhibitors: Basic Concepts and Clinical
`Applications, 1 EPIGENETICS 7–13 (2006) (“Mund”)
`
`National Cancer Institute, Bioassay of 5-azacytidine for Possible
`Carcinogenicity, U.S. DEP’T OF HEALTH, EDUC., AND WELFARE
`(1978) (“National Cancer Institute”)
`
`Notari, R. & De Young, J., Kinetics and Mechanisms of
`Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous
`Solutions, 64 J. OF PHARMACEUTICAL SCI. 1148–57 (1975)
`(“Notari”)
`
`Onureg® Label
`
`International Pat. Appl. Pub. No. WO2009/139888
`(“WO2009/139888”)
`
`Piťhová, P., et al., Nucleic Acids Components and Their Analogues.
`LXVI.* Hydrolysis of 5-Azacytidine and its Connection with
`Biological Activity, 30 COLLECT. CZECH. CHEM. COMMUN. 2801–11
`(1965) (“Piťhová”)
`
`REMINGTON, THE SCIENCE AND PRACTICE OF PHARMACY 802–938
`(21st Ed. 2005) (“Remington 2005”)
`
`Stresemann, C. & Lyko, F., Modes of action of the DNA
`methyltransferase inhibitors azacytidine and decitabine, 123 INT. J.
`CANCER 8–13 (2008) (“Stresemann”)
`
`U.S. Pat. Pub. No. US20040186065A1 (“Ionescu-065”)
`
`Weiss, A., et al., Phase I Study of 5-Azacytidine 56 CANCER
`CHEMOTHERAPY REP. 413–19 (1972) (“Weiss”)
`
`8
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2032
`
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`2045
`
`2046
`
`Celgene v. Accord 1:21-cv-01795-RGA Doc 40
`
`U.S. Pat. No. 7,189,740 (“Zeldis”)
`
`Glover, A., et al., Azacitidine: 10 Years Later, 71 CANCER
`TREATMENT REP. 737–46 (1987) (“Glover”)
`
`U.S. Pat. No. 6,887,855 (“Ionescu-855”)
`
`U.S. Pat. No. 7,078,518 (“Ionescu-518”)
`
`U.S. Pat. No. 7,772,199 (“Ionescu-199”)
`
`U.S. Pat. Pub. No. US20060247189 (“Ionescu-189”)
`
`U.S. Pat. Pub. No. US20100298253 (“Ionescu-253”)
`
`Ward, M., et al., An oral dosage formulation of azacytidine: A pilot
`pharmacokinetic study, J. OF CLINICAL ONCOLOGY (2007) (“Ward”)
`
`International Pat. Appl. Pub. No. WO2008/028193
`(“WO2008/028193”)
`
`Gibson, M., Pharm. PREFORMULATION AND FORMULATION: A
`PRACTICAL GUIDE FROM CANDIDATE DRUG SELECTION TO
`COMMERCIAL DOSAGE FORM 1-11 (2001) (“Gibson Supplemental”)
`
`LIEBERMAN, H., ET AL., PHARMACEUTICAL DOSAGE FORMS 2 (2nd
`Ed. 1990) (“Lieberman Vol. 2”)
`
`International Pat. Appl. Pub. No. WO2004/082618
`(“WO2004/082618”)
`
`Celgene v. Accord 1:21-cv-01795-RGA Doc 35
`
`Reserved
`
`9
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2047
`
`2048
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`2054
`
`2055
`
`2056
`
`2057
`
`2058
`
`2059
`
`2060
`
`Savage, D., et al., The Gastrointestinal Epithelium and its
`Autochthonous Bacterial Flora, 127 J. OF EXPERIMENTAL MEDICINE
`67–81 (1967) (“Savage”)
`
`Pawar, et al., Integration of Biorelevant Pediatric Dissolution
`Methodology into PBPK Modeling to Predict In Vivo Performance
`and Bioequivalence of Generic Drugs in Pediatric Populations: A
`Carbamazepine Case Study, 25 AAPS J. 67 (2023) (“Pawar”)
`
`Deposition Transcript of Hannah K. Batchelor (“Batchelor Tr.”)
`
`Deposition Transcript of Graham Buckton, Ph.D. (“Buckton Tr.”)
`
`Declaration of Corey Berkland, Ph.D. (“Berkland Decl.”)
`
`Declaration of George M. Grass, Ph.D. (“Grass Decl.”)
`
`Declaration of William G. Blum, M.D. (“Blum Decl.”)
`
`Declaration of Jeffrey B. Etter, Ph.D. (“Etter Decl.”)
`
`U.S. Food and Drug Admin., FDA approves Onureg® (azacitidine
`tablets) for acute myeloid leukemia (2020),
`https://www.fda.gov/drugs/resources-information-approved-
`drugs/fda-approves-onureg-azacitidine-tablets-acute-myeloid-
`leukemia (“FDA Approves Onureg®”)
`
`Canadian Product 200mg Onureg® Product Information
`
`Canadian Product 300mg Onureg® Product Information
`
`Canadian Product Monograph Onureg®
`
`European Commission Decision 17.6.21
`
`Perrie, Y. & Rades, T., PHARMACEUTICAL: DRUG DELIVERY AND
`TARGETING (2010) (“FASTtrack”)
`
`10
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2072
`
`Reserved
`
`Onureg® Label
`
`Gibson, M., Pharm. PREFORMULATION AND FORMULATION: A
`PRACTICAL GUIDE FROM CANDIDATE DRUG SELECTION TO
`COMMERCIAL DOSAGE FORM 1-11 (2001) (“Gibson Supplemental”)
`
`ALTMAN, R, & SARG, M., CANCER DICTIONARY: REVISED EDITION
`16–17, 197 (2000) (“Altman”)
`
`ALLEN, L, ET AL., ANSEL’S PHARM. DOSAGE FORMS AND DRUG
`DELIVERY SYS. (8th Ed. 2005) (“Ansel”)
`
`Antonsson, B., et al., Effect of 5-Azacytidine and Congeners on DNA
`Methylation and Expression of Deoxycytidine Kinase in the Human
`Lymphoid Cell Lines CCRF/CEM/0 and CCRF/CEM/dCk-1, 47
`CANCER RESEARCH 3762–78 (1987) (“Antonsson”)
`
`AULTON, M., PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM
`DESIGN (1988) (“Aulton”)
`
`Bankhead, C., Year in Review: Acute Myeloid Leukemia, MedPage
`Today (Nov. 29, 2020),
`https://www.medpagetoday.com/hematologyoncology/leukemia/899
`09 (“Bankhead”)
`
`Reserved
`
`Ben-Kasus, T., et al., Metabolic activation of zebularine, a novel
`DNA methylation inhibitor, in human bladder carcinoma cells, 70
`BIOCHEM. PHARM. 121–33 (2005) (“Ben-Kasus”)
`
`Carter, J., et al., Targeting multiple signaling pathways: the new
`approach to acute myeloid leukemia therapy, 5 SIGNAL
`TRANSDUCTION AND TARGETED THERAPY 288 (2020) (“Carter”)
`
`Choi, Y., et al., Oral Maintenance Chemotherapy with 6-
`Mercaptopurine and Methotrexate in Patients with Acute Myeloid
`
`11
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`2081
`
`Leukemia Ineligible for Transplantation, 30 KOREAN ACADEMY OF
`MED. SCI. 1416–22 (2015) (“Choi”)
`
`Cogle, C., et al., Oral Azacitidine (CC-486) for the Treatment of
`Myelodysplastic Syndromes and Acute Myeloid Leukemia, 20
`ONCOLOGIST 1404–12 (2015) (“Cogle”)
`
`Covey, J., et al., Differences in DNA Damage Produced by
`Incorporation of 5-Aza-2’-deoxycytidine or 5,6-Dihydro-5-
`azacytidine into DNA of Mammalian Cells, 46 CANCER RESEARCH
`5511–17 (1986) (“Covey”)
`
`CRAIG, C. & STITZEL, R., MODERN PHARMACOLOGY WITH CLINICAL
`APP. (6th Ed. 2004) 48–55 (“Craig”)
`
`Curtiss, F., Pharmacy Benefit Spending on Oral Chemotherapy
`Drugs, 12 J. OF MANAGED CARE PHARMACY 570–77 (2006)
`(“Curtiss”)
`
`DeSimone, J., et al., Tetrahydrouridine, Cytidine, Analogues, and
`Hemoglobin F, 18 AM. J. OF HEMATOLOGY 283–88 (1985)
`(“DeSimone”)
`
`Dressman, J., et al., Dissolution Testing as a Prognostic Tool for
`Oral Drug Absorption: Immediate Release Dosage Forms, 15
`PHARM. RESEARCH 11–22 (1998) (“Dressman”)
`
`Case Reports, 72 BRITISH J. OF HAEMATOLOGY 467–68 (1989)
`(“Dunbar”)
`
`Ellison, R., et al., Arabinosyl Cytosine: A Useful Agent in the
`Treatment of Acute Leukemia in Adults, 32 J. OF HEMATOLOGY 507–
`23 (1968) (“Ellisson”)
`
`The ASCO Post Staff, “FDA Approves Oral Azacitidine as
`Maintenance Therapy for Adults With AML in First Remission”
`(Sept. 25, 2020), https://ascopost.com/issues/september-25-
`2020/fda-approves-oral-azacitidine-as-maintenance-therapy-for-
`
`12
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2082
`
`2083
`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`2089
`
`2090
`
`adults-with-aml-in-first-remission/ (“FDA Approves Oral
`Azacitidine”)
`
`Frisch, A., et al., How we treat older patients with acute myeloid
`leukaemia, 191 BRITISH J. OF HAEMATOLOGY 682–91 (2020)
`(“Frisch”)
`
`Futterman, B., et al., Studies on the Cytostatic Action
`Phosphorylation and Deamination of 5-Azacytidine and 5,6-
`Dihydro-5-Azacytidine in Hela Cells, 27 BIOCHEM. PHARM. 907–9
`(1978) (“Futterman”)
`
`Garcia-Manero, G., et al., Phase I Study of Oral Azacitidine in
`Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia,
`and Acute Myeloid Leukemia, 29 J. OF CLIN. ONCOLOGY 2521–27
`(2011) (“Garcia-Manero”)
`
`Goldin, A., et al., Relation of Structure of Purine and Pyrimidine
`Nucleosides to Antitumor Activity, 1 CANCER CHEMOTHERAPY 1–29,
`268 (1968) (“Goldin”)
`
`Griffiths, E., Oral hypomethylating agents: beyond convenience in
`MDS, 2021 HEMATOLOGY 439–47 (2021) (“Griffiths”)
`
`Grønbæk , K., et al., Epigenetic Changes in Cancer as Potential
`Targets for Prophylaxis and Maintenance Therapy, 103 BASIC &
`CLINICAL PHARM. & TOXICOLOGY 389–96 (2008) (“Grønbæk”)
`
`Hrodek, O. & Vesely J., 5-Azacytidine in Childhood Leukemia, 18
`NEOPLASMA 493–503 (1971) (“Hrodek”)
`
`Kantarjian, H., et al., Acute Myeloid Leukemia: Historical
`Perspective and Progress in Research and Therapy Over 5 Decades,
`21 CLIN. LYMPHOMA, MYELOMA AND LEUKEMIA 580–97 (2021)
`(“Kantarjian”)
`
`Karon, M., et al., 5-Azacytidine: A New Active Agent for the
`Treatment of Acute Leukemia, 42 BLOOD 359–65 (1973) (“Karon”)
`
`13
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2091
`
`2092
`
`2093
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`Kipp, D. & Wei, A., The path to approval for oral hypomethylating
`agents in acute myeloid leukemia and myelodysplastic syndromes,
`17(20) FUTURE ONCOL. 2563–71 (2021) (“Kipp”)
`
`Kornblith, A., et al., Impact of Azacytidine on the Quality of Life of
`Patients With Myelodysplastic Syndrome Treated in a Randomized
`Phase III Trial: A Cancer and Leukemia Group B Study, 20 J. OF
`CLIN. ONCOLOGY 2441–52 (2002) (“Kornblith”)
`
`Lammers, P. & Cashen, A., Azacitidine: A Review of its Use in the
`Management of Myelodysplastic Syndromes, 1 CLIN. MED.
`THERAPEUTICS 1189–97 (2009) (“Lammers”)
`
`Lin, R., Allogeneic Transplantation for Older Patients with Acute
`Myeloid Leukemia: The Dawn of a New Era, 28 TRANSPLANTATION
`AND CELLULAR THERAPY 793–94 (2022) (“Lin 2022”)
`
`Liu, H., Emerging agents and regimens for AML, 14 J.
`HEMATOLOGY & ONCOLOGY 19 (2021) (“Liu”)
`
`Lomen, V., et al., “Phase I Study of 5-Azacytidine Using 24 Hrs
`Continuous Infusion for 5 Days” 16 PROCEEDINGS OF THE AM. ASS.
`FOR CANCER RESEARCH & AM. SOC. OF CLIN. ONCOLOGY 52 (Mar.
`1975) (“Lomen”)
`
`Lӧwenberg, B., et al., Mitoxantrone Versus Daunorubicin in
`Induction-Consolidation Chemotherapy, 16 J. OF CLIN. ONCOLOGY
`872–81 (1998) (“Lӧwenberg”)
`
`Ma, X., et al., Myelodysplastic Syndromes: Incidence and Survival
`in the United States, 109 AM. CANCER SOC. 1536–42 (2007) (“Ma”)
`
`Reserved
`
`McCredie, K., Treatment of Acute Leukemia with 5-Azacytidine
`(NSC-102816), 57 CANCER CHEMOTHERAPY REP. 319–23 (1973)
`(“McCredie”)
`
`14
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2101
`
`2102
`
`2103
`
`2104
`
`2105
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`
`2111
`
`Neil, G., et al., Enhancement by Tetrahydrouridine (NSC-112907) of
`the Oral Activity of 5-Azacytidine (NSC-102816) in L1210 Leukemic
`Mice, 59 CANCER CHEMOTHERAPY REP. 459–65 (1975) (“Neil”)
`
`Odenike, O., Incorporating novel approaches in the management of
`MDS beyond conventional hypomethylating agents, AM. SOC. OF
`HEMATOLOGY 460–69 (2017) (“Odenike”)
`
`Goodman, A., “Oral CC-486 Maintenance Therapy Extends Survival
`in Older Patients with AML” THE ASCO POST (Jan. 25, 2020),
`https://ascopost.com/issues/january-25-2020/oral-cc-486-
`maintenance-therapy-extends-survival-in-older-patients-with-aml/
`(“Oral CC-486”)
`
`Perl, A., The role of targeted therapy in the management of patients
`with AML, 1 BLOOD ADVANCES AND HEMATOLOGY 2281–94 (2017)
`(“Perl”)
`
`Reserved
`
`Reserved
`
`PORTA, M., A DICTIONARY OF EPIDEMIOLOGY 226–27 (5th Ed. 2008)
`(“Porta”)
`
`Preisler, H., et al., Comparison of Three Remission Induction
`Regimens and Two Postinduction Strategies for the Treatment of
`Acute Nonlymphocytic Leukemia, 69 BLOOD 1441–49 (1987)
`(“Preisler”)
`
`Reserved
`
`Récher, C., The beginning of a new therapeutic era in acute myeloid
`leukemia, 2 J. HAEMATOLOGY 823–33(2021) (“Récher”)
`
`Reville, P., Maintenance Therapy in AML, 10 FRONTIERS IN
`ONCOLOGY (2021) (“Reville”)
`
`15
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2112
`
`2113
`
`2114
`
`2115
`
`2116
`
`2117
`
`2118
`
`2119
`
`2120
`
`2121
`
`2122
`
`Shnider, B., et al., A Phase I Study of 5-Azacytidine (NSC-102816),
`16(4) J. OF CLIN. PHARMACOLOGY 205–12 (1976) (“Shnider”)
`
`Reserved
`
`Slater, H., Phase 3 QUAZAR AML-001 Trial Finds Oral Azacitidine
`Extends Survival in Older Adults with AML, Cancer Network (Jan.
`12, 2021) (“Slater”)
`
`Sochacka-Ćwikła, A., et al., FDA-Approved Drugs for
`Hematological Malignancies—The Last Decade Review, 14
`CANCERS 87 (2022) (“Sochacka-Ćwikła”)
`
`Sorm, F., et al., 5-Azacytidine, a New, Highly Effective
`Cancerostatic, 20 INSTITUTE OF ORGANIC CHEM. AND BIOCHEM.
`202–3 (1964) (“Sorm”)
`
`Reserved
`
`Sorrentino, V., et al., Hypomethylating Chemotherapeutic Agents as
`Therapy for Myelodysplastic Syndromes and Prevention of Acute
`Myeloid Leukemia, 14 PHARMACEUTICALS 641 (2021) (“Sorrentino”)
`
`Southall, J., “Oral azacytidine extends survival for patients with
`AML in remission after chemotherapy” HemOncToday (Jan. 5,
`2021) (“Southall”)
`
`Steensma, D., ASH 2010 Meeting Report—Top 10 clinically-
`oriented abstracts in myelodysplastic syndromes (MDS), 86 AM. J.
`OF HEMATOLOGY 385–91 (2011) (“Steensma”)
`
`Surbone, A., et al., Phase I and Pharmacokinetic Study of
`Arabinofuranosyl-5-azacytosine (Fazarabine, NSC 281272), 50
`CANCER RESEARCH 1220–25 (1990) (“Surbone”)
`
`Toutain, P. & Bousquet-Melou, A., Bioavailability and its
`assessment, 27 J. VET. PHARMACOLOGY. THERAP. 455–66 (2004)
`(“Toutain”)
`
`16
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2123
`
`2124
`
`2125
`
`2126
`
`2127
`
`2128
`
`2129
`
`2130
`
`2131
`
`U.S. Provisional 60/824320 File History (“60/824,320”)
`
`U.S. Patent Application US 2008/0057086 (“US2008/0057086”)
`
`Vigil, C., et al., Safety and efficacy of azacitidine in myelodysplastic
`syndromes, 4 DRUG DESIGN, DEVELOPMENT AND THERAPY 221–29
`(2010) (“Vigil”)
`
`Vogler, W., et al., “Remission Induction in Refractory Myeloblastic
`Leukemia with Continuous Infusion of 5-Azacytidine” 16
`PROCEEDINGS OF THE AM. ASS. FOR CANCER RESEARCH & AM. SOC.
`OF CLIN. ONCOLOGY 155 (Mar. 1975) (“VoglerI”)
`
`Vogler, W., 5-Azacytidine (NSC 102816): A New Drug for the
`Treatment of Myeloblastic Leukemia, 48 BLOOD 331–37 (1976)
`(“VoglerII”)
`
`Von Hoff, D., et al., 5-Azacytidine A New Anticancer Drug with
`Effectiveness in Acute Myelogenous Leukemia, 85 ANNALS OF
`INTERNAL MEDICINE 237–45 (1976) (“VonHoff”)
`
`Wei, A., et al., Long-term survival with oral azacitidine for patients
`with acute myeloid leukemia in first remission after chemotherapy,
`98 AM. J. OF HEMATOLOGY E84–87 (2023) (“Wei”)
`
`Weill Cornell Medicine, “New maintenance treatment for acute
`myeloid leukemia prolongs the lives of patients” NEW ENGLAND J.
`OF MED. (Jan. 22, 2021),
`https://news.weill.cornell.edu/news/2021/01/new-maintenance-
`treatment-for-acute-myeloid-leukemia-prolongs-the-lives-of-
`patients, (“Weill Cornell”)
`
`Zielinski, W. & Sprinzl, M., Chemical synthesis of 5-azacytidine
`nucleotides and preparation of tRNAs containing 5-azacytidine in its
`3’-terminus, 12 NUCLEIC ACIDS RESEARCH 5025–36 (1984)
`(“Zielinski”)
`
`17
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2132
`
`2133
`
`2134
`
`2135
`
`2136
`
`2137
`
`2138
`
`2139
`
`2140
`
`2141
`
`2142
`
`2143
`
`2144
`
`Ziemba, A., et al., Development of an Oral Form of Azacytidine:
`2‘3‘5Triacetyl-5-Azacytidine, 2011 CHEMOTHERAPY RESEARCH AND
`PRACTICE 1–9 (2011) (“Ziemba”)
`
`Exemestane Label (“Exemestane”)
`
`Anastrozole Label (“Anastrozole”)
`
`Letrozole Label (“Letrozole”)
`
`Blum W, et al., Maintenance therapy with decitabine in younger
`adults with acute myeloid leukemia in first remission: a phase 2
`Cancer and Leukemia Group B Study (CALGB 10503), 31
`LEUKEMIA 34–39 (2017) (“Blum”)
`
`Cytarabine Label (“Cytarabine”)
`
`Dacogen Label (“Dacogen”)
`
`Mitoxantrone Label (“Mitoxantrone”)
`
`Finkel, M., The Orphan Drug Act and the Federal Government’s
`Orphan Products Development Program, 99 PUBLIC HEALTH REPS.
`313–16 (1984) (“Finkel”)
`
`Martinez, M. & Amidon, G., A Mechanistic Approach to
`Understanding the Factors Affecting Drug Absorption, 42 J. OF
`CLIN. PHARMACOLOGY 620–43 (2002) (“Martinez”)
`
`European Medicines Agency, Assessment Report of Onureg
`EMA/308711/2021(“European Medicines Report”)
`
`Hirayama, H., et al., Distribution and Excretion of Cyclocytidine in
`Monkeys, Dogs, and Rats, 65 GANN 153–61 (1974) (“Hirayama”)
`
`LIEBERMAN, H., ET AL., PHARMACEUTICAL DOSAGE FORMS: TABLETS
`1 (2nd Ed. 1989) (“Lieberman Vol. 1”)
`
`18
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`2145
`
`2146
`
`2147
`
`2148
`
`2149
`
`2150
`
`2151
`
`2152
`
`2153
`
`DEAN, D., ET AL., PHARMACEUTICAL PACKAGING TECHNOLOGY
`(2000) (“Dean”)
`
`GENNARO, A., REMINGTON’S PHARMACEUTICAL SCIENCES 257–309,
`1519–44, 1615–32 (18th Ed. 1990) (“Remington 1990”)
`
`REMINGTON, THE SCIENCE AND PRACTICE OF PHARMACY 319–37,
`702–19, 745–75, 1025–36 (21st Ed. 2005) (“Remington 2005 II”)
`
`GIBALDI, M. & PERRIER, D., PHARMACOKINETICS (2nd Ed. 2007)
`271–353 (“Gilbaldi”)
`
`First Expert Declaration of James L. Mullins, Ph.D.
`
`Huls, G., et al. Azacitidine maintenance after intensive
`chemotherapy improves DFS in older AML patients, 133 BLOOD,
`THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY 1457–64
`(2019) (“Huls”)
`
`Second Expert Declaration of James L. Mullins, Ph.D.
`
`Declaration of Andrew J. Danford in Support of Unopposed Motion
`for Admission Pro Hac Vice
`
`Declaration of Nora Q.E. Passamaneck in Support of Unopposed
`Motion for Admission Pro Hac Vice
`
`19
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`CERTIFICATE OF SERVICE
`I hereby certify that on October 25, 2023, true and correct copies of the
`
`following materials:
`
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of
`
`Nora Q.E. Passamaneck
`
` Exhibit 2153, Declaration of Nora Q.E. Passamaneck in Support of
`
`Unopposed Motion for Pro Hac Vice Admission
`
` Patent Owner’s Exhibit List
`
`were served electronically via email, on the following attorneys of record:
`
`Vishal C. Gupta (Reg. No. 67,284)
`John J. Molenda (Reg. No. 47,804)
`Tyler Doh (Reg. No. 80,274)
`Steptoe & Johnson LLP
`1114 Avenue of the Americas
`New York, NY 10036
`Tel: (212) 506-3900
`Fax: (212)-506-3950
`Robert Kappers (Reg. No. 70,202)
`Steptoe & Johnson LLP
`227 West Monroe Street
`Suite 4700
`Chicago, IL 60606
`Tel: (312)-577-1300
`Azacitidine@Steptoe.com
`
`
`
`
`
`
`
`
`
`
`
`IPR2023-00512
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of Nora Q.E.
`Passamaneck
`
`By: /Gabriel J. Rosanio/
`
`Gabriel J. Rosanio, Ph.D., (Reg. No. 81,426)
`Wilmer Cutler Pickering Hale and Dorr LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`Tel: 212-295-6446
`Email: Gabriel.Rosanio@wilmerhale.com
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
